Ovensa is a Canadian preclinical stage company committed to advance its siRNA lead candidate silencing galectin-1 overexpression in the tumor microenvironment to improve therapeutic outcomes of an immuno-oncology anti-PD-1 checkpoint inhibitor as a combination therapy in head & neck cancer. The company is also advancing its collaboration programs with pharmaceutical companies to develop precision and combination medicines through its proprietary TRIOZAN™ Platform for specific indications.
Ovensa is a Canadian preclinical stage company committed to advance its siRNA lead candidate silencing galectin-1 overexpression in the tumor microenvironment to improve therapeutic outcomes of an immuno-oncology anti-PD-1 checkpoint inhibitor as a combination therapy in head & neck cancer. The company is also advancing its collaboration programs with pharmaceutical companies to develop precision and combination medicines through its proprietary TRIOZAN™ Platform for specific indications.
Company Information
- Industry
- Company Type
- Privately Held
- Founded
- 2012
- Employee Range
- 1-10
- Revenue Range
- Not available
Location
- Address
- City
- Aurora
- Region
- Ontario
- Postal Code
- Country
- Canada